title: Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer.
abstract: OBJECTIVE
  Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer.
  
  
  METHODS
  A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues.
  
  
  RESULTS
  Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signal was scarcely detected in tissues from CP patients or normal surrounding tissue.
  
  
  CONCLUSIONS
  These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.
authors: From the *Department of Surgery, Osaka University Graduate School of Medicine, Osaka; †Department of Surgery and Institute for Clinical Research National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima; ‡Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka; §Department of Gastroenterology, Ogaki Municipal Hospital, Gifu; ║Wako Pure Chemical Industries, Ltd; ¶Department of Gastroenterology and Hepatology, Japan Community Health Care Organization Osaka Hospital; and #Laboratory for Immune Signal, National Institute of Biomedical Innovation, Osaka, Japan.
authors: Kenta
authors: K
authors: Furukawa
authors: Koichi
authors: K
authors: Kawamoto
authors: Hidetoshi
authors: H
authors: Eguchi
authors: Masahiro
authors: M
authors: Tanemura
authors: Tsukasa
authors: T
authors: Tanida
authors: Yoshito
authors: Y
authors: Tomimaru
authors: Hirofumi
authors: H
authors: Akita
authors: Naoki
authors: N
authors: Hama
authors: Hiroshi
authors: H
authors: Wada
authors: Shogo
authors: S
authors: Kobayashi
authors: Yuji
authors: Y
authors: Nonaka
authors: Shinji
authors: S
authors: Takamatsu
authors: Shinichiro
authors: S
authors: Shinzaki
authors: Takashi
authors: T
authors: Kumada
authors: Shinji
authors: S
authors: Satomura
authors: Toshifumi
authors: T
authors: Ito
authors: Satoshi
authors: S
authors: Serada
authors: Tetsuji
authors: T
authors: Naka
authors: Masaki
authors: M
authors: Mori
authors: Yuichiro
authors: Y
authors: Doki
authors: Eiji
authors: E
authors: Miyoshi
authors: Hiroaki
authors: H
authors: Nagano
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000473:pathology; D011237:Predictive Value of Tests; D012372:ROC Curve; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D006023:Glycoproteins; C015246:LRG1 protein, human